(CRISPR Therapeutics) CRISPR Therapeutics posted positive updated results from the ongoing Phase 1 CARBON trial evaluating the safety and efficiency of CTX110TM, its allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies.
A single dose of CTX100 at Dose Level 2 resulted in a 58% overall response rate (ORR) and a 38% complete response (CR) rate in large B-cell lymphoma (LBCL).
Durable responses in LBCL were achieved with a six-month CR rate of 21% and the longest response ongoing at more than 18 months after initial infusion.
Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, stated that they were excited to share positive data from their CARBON trial that shows that CTX100 could provide patients with large B-cell lymphomas an available ‘off-the-shelf’ therapy.
Kulkarni further stated that the firm has the potential to improve on the observed efficiency with a consolidation dosing strategy. Going forward, the company is looking to expand CARBON into a potential registrational trial in Q1 of 2022.
The company continues to advance the rest of its immune-oncology portfolio and expand its manufacturing capabilities in its new state-of-the-art manufacturing facility in Massachusetts.
CRSP down -9.35%.
